Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|March 18, 2019
MALDI-8020: Small size. Massive impact
Author(s)Shimadzu Europa GmbH
The MALDI-8020 is the latest in a long line of MALDI-TOF products from Shimadzu. This benchtop, linear MALDI-TOF mass spectrometer delivers outstanding performance in a compact footprint, making it an ideal choice for today’s increasingly demanding laboratories.
Advertisement
The
Key features:
- Linear mode (positive ion) MALDI-TOF
- 200 Hz solidâstate laser, 355 nm
- Load-lock chamber for fast sample introduction
- UV laserâbased source cleaning (patented)
- Small size due to benchtop design with a compact footprint
- Quiet operation (<55 dB)
Linear mode instruments have traditionally been the instruments of choice in MALDI-TOF-based quality control (QC) and profiling workflows, and the
Contact Details:
Company Name: Shimadzu Europa GmbH
Website:
Email: shimadzu@shimadzu.eu
Advertisement
Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5